Masato Tomomitsu

Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate

Hiroaki Matsuno, Masato Tomomitsu, Atsushi Hagino et al. · Annals of the Rheumatic Diseases · 2017 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Fluorinated Benzo(h)quinolines and Benzo(f)quinolines.

Ken‐ichi Saeki, Masato Tomomitsu, Yutaka Kawazoe et al. · Chemical and Pharmaceutical Bulletin · 1996 · 29 citations · Full text

Natural Sciences, Chemistry, Toxicology +10

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

Min‐Chan Park, Hiroaki Matsuno, Jinseok Kim et al. · Arthritis Research & Therapy · 2019 · 21 citations · Full text

Medicine, Clinical Sciences, Immunology +12

A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis

Hiroshi Hagino, Ryoichi Narita, Yuichiro Yokoyama et al. · Osteoporosis International · 2019 · 12 citations · Full text

Medicine, Orthopedic Surgery, Pharmacotherapy +17